Funding round
NewLimit Series C
NewLimit, which works in epigenetic reprogramming medicine development in South San Francisco, raised $435M in a Series C round announced on 2 Jun 2026, led by Founders Fund, at a $3.10B post-money valuation. 10 firms took part, 6 of them already investors. It is NewLimit's fourth venture round on record; the one before was a Growth in Oct 2025.
$435M
Amount raised
$3.10B
Post-money valuation
10
Investors
1 lead
1.9x
Step-up from the Growth
$1.62B in Oct 2025
14%
Stake sold
new money over the post-money
Valuation
What this round says about the price
This round priced NewLimit at $3.10B after the new money, 1.9 times the $1.62B of its Growth (Oct 2025). The $435M bought investors about 14% of the company. It came 8 months after NewLimit's Growth. It is 67% of the $650M NewLimit has raised in the venture rounds on record. No later venture round is on record for NewLimit.
NewLimit's funding rounds
NewLimit has 4 venture rounds on record. This one is highlighted.
Investors
Who put money in
Founders Fund led the round with 9 other firms. Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross and Valor and 2 more had backed NewLimit before.
Lead investor
- Founders Fund backs 368 venture-backed companies new investor
Also in the round
- Thrive Capital backs 130 venture-backed companies new investor
- Greenoaks backs 77 venture-backed companies new investor
- backs 111 venture-backed companies new investor
- Kleiner Perkins backs 285 venture-backed companies existing investor
- Abstract existing investor
- Nat Friedman/Daniel Gross existing investor
- Valor backs 143 venture-backed companies existing investor
- Eli Lilly Ventures existing investor
- backs 55 venture-backed companies existing investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
27 Series C rounds in Biotechnology within a year either side disclosed an amount; the median was $56M, and this round was 7.8 times the median. The closest in time, other companies' Series C rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 30 Jun 2026 | $85M | not disclosed | Third Rock Ventures and Nextech Invest |
| Biotechnology | 17 Jun 2026 | $65M | not disclosed | Ascenta Capital and Janus Henderson Investors |
| Biotechnology | 18 May 2026 | $50M | not disclosed | OrbiMed |
| Biotechnology | 16 Jul 2026 | $9.0M | not disclosed | not named |
| Biotechnology | 27 Aug 2026 | $120M | not disclosed | RA Capital and Strategic Investor |
| Biotechnology | 15 Apr 2026 | $108M | not disclosed | not named |
| Biotechnology | 11 Aug 2026 | $90M | not disclosed | Octagon Capital and Janus Henderson Investors |
| Biotechnology | 16 Apr 2026 | $56M | not disclosed | M Ventures |
Sources
Where this comes from
Reported by 7 sources.
Questions
Frequently asked
How much did NewLimit raise in its Series C round?
NewLimit raised $435M in its Series C round, announced in Jun 2026.
Who led NewLimit's Series C round?
Founders Fund led it, with Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins and Abstract and 4 more.
What was NewLimit's valuation at the Series C round?
$3.10B post-money.
How does it compare with other Series C rounds in Biotechnology?
27 Series C rounds in Biotechnology within a year either side disclosed an amount; the median was $56M, and this round was 7.8 times the median.